{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:33:58Z","timestamp":1792460038818,"version":"4.5.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.clindermatol.2012.08.016","type":"journal-article","created":{"date-parts":[[2013,4,19]],"date-time":"2013-04-19T07:17:58Z","timestamp":1366355878000},"page":"290-297","source":"Crossref","is-referenced-by-count":125,"title":["Chemotherapy in the management of advanced cutaneous malignant melanoma"],"prefix":"10.1016","volume":"31","author":[{"given":"Jason J.","family":"Luke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary K.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2012.08.016_bb0005","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1053\/sonc.2002.35238","article-title":"Metastatic melanoma: chemotherapy","volume":"29","author":"Bajetta","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0010","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1053\/sonc.2002.35237","article-title":"Systemic chemotherapy for the treatment of metastatic melanoma","volume":"29","author":"Li","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0015","first-page":"CD001215","article-title":"Systemic treatments for metastatic cutaneous melanoma","volume":"2","author":"Crosby","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0020","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"Middleton","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0025","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.ejca.2011.04.030","article-title":"Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032)","volume":"47","author":"Patel","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0030","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0035","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/CMR.0b013e328345af95","article-title":"Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution","volume":"21","author":"Boeckmann","year":"2011","journal-title":"Melanoma Res"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0040","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s002800050657","article-title":"Effect of single and multiple administration of an O6-benzylguanine\/temozolomide combination: an evaluation in a human melanoma xenograft model","volume":"40","author":"Wedge","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0045","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/sj.bjc.6605796","article-title":"MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome","volume":"103","author":"Hassel","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0050","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1158\/1078-0432.CCR-05-2198","article-title":"Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors","volume":"12","author":"Ranson","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0055","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2007.10.8217","article-title":"Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma","volume":"25","author":"Ranson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0060","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.2007.14.5292","article-title":"Phase II study of extended-dose temozolomide in patients with melanoma","volume":"26","author":"Rietschel","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0065","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1002\/cncr.25035","article-title":"Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects","volume":"116","author":"Neyns","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0070","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0075","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s00262-009-0671-1","article-title":"Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model","volume":"58","author":"Banissi","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0080","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1200\/JCO.2004.07.060","article-title":"Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications","volume":"22","author":"Su","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0085","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.4049\/jimmunol.174.5.2591","article-title":"CD8+ T cell immunity against a tumor\/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells","volume":"174","author":"Antony","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0090","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0095","series-title":"Molecular diagnosis, prevention and therapy of melanoma","first-page":"219","article-title":"The role of cytotoxic chemotherapeutic agents either alone or in combination with biological response modifiers","author":"Atkins","year":"1997"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0100","series-title":"Cutaneous melanoma","first-page":"498","article-title":"Chemotherapy for metastatic melanoma","author":"Houghton","year":"1992"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0105","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1200\/JCO.2004.04.165","article-title":"Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study","volume":"22","author":"Avril","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0110","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.1984.2.4.316","article-title":"Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study","volume":"2","author":"Quagliana","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0115","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00000421-198310000-00009","article-title":"Vindesine for metastatic malignant melanoma. A phase II trial","volume":"6","author":"Nelimark","year":"1983","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0120","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/CMR.0b013e328311aaa1","article-title":"A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma","volume":"18","author":"Bedikian","year":"2008","journal-title":"Melanoma Res"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0125","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/cncr.20183","article-title":"A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study","volume":"100","author":"Whitehead","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0130","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00001813-200501000-00007","article-title":"Phase II trial of vinorelbine tartrate in patients with treatment-naive metastatic melanoma","volume":"16","author":"Jimeno","year":"2005","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0135","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF00194546","article-title":"A phase II study of taxol in patients with malignant melanoma","volume":"9","author":"Einzig","year":"1991","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0140","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/0959-8049(94)90456-1","article-title":"Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group","volume":"30A","author":"Aamdal","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0145","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/CMR.0b013e32832a1e2f","article-title":"Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients","volume":"19","author":"Homsi","year":"2009","journal-title":"Melanoma Res"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0150","first-page":"1038","article-title":"Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel","volume":"8","author":"Ibrahim","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0155","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/cncr.24720","article-title":"A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma","volume":"116","author":"Hersh","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0160","first-page":"171","article-title":"Phase II trial of carboplatin in advanced malignant melanoma","volume":"71","author":"Evans","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0165","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/1097-0142(19891115)64:10<2024::AID-CNCR2820641010>3.0.CO;2-V","article-title":"A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma","volume":"64","author":"Legha","year":"1989","journal-title":"Cancer"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0170","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ijc.2910500410","article-title":"Effective combination chemo\/hormonal therapy for malignant melanoma: experience with three consecutive trials","volume":"50","author":"McClay","year":"1992","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0175","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1200\/JCO.1998.16.2.664","article-title":"Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study","volume":"16","author":"Margolin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0180","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1200\/JCO.1996.14.7.2083","article-title":"Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Rusthoven","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0185","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.1999.17.6.1884","article-title":"Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma","volume":"17","author":"Creagan","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0190","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1200\/JCO.20.2.420","article-title":"Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group","volume":"20","author":"Bafaloukos","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0195","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","article-title":"Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma","volume":"17","author":"Chapman","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0200","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/cncr.25659","article-title":"A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group Study, N057E(1)","volume":"117","author":"Kottschade","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0205","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00008390-200508000-00010","article-title":"Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma","volume":"15","author":"Vuoristo","year":"2005","journal-title":"Melanoma Res"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0210","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/oxfordjournals.annonc.a010762","article-title":"Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha","volume":"7","author":"Legha","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0215","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1200\/JCO.1998.16.5.1752","article-title":"Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma","volume":"16","author":"Legha","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0220","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1200\/JCO.2002.07.044","article-title":"Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial","volume":"20","author":"Eton","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0225","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1200\/JCO.2008.17.5448","volume":"26","author":"Atkins","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0230","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/annonc\/mdl007","article-title":"Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma","volume":"17","author":"Bajetta","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0235","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1200\/JCO.2005.03.202","article-title":"Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group","volume":"23","author":"Keilholz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0240","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.20.6.1600","article-title":"Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial","volume":"20","author":"Ridolfi","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0245","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1200\/JCO.2007.12.0253","article-title":"Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients","volume":"25","author":"Ives","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0250","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1200\/JCO.2007.11.9552","article-title":"More support for the judicious use of high-dose interleukin-2 in patients with advanced melanoma","volume":"25","author":"McDermott","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0255","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1200\/JCO.2006.10.2822","article-title":"Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy","volume":"25","author":"Tarhini","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0260","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0265","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0270","doi-asserted-by":"crossref","first-page":"7732","DOI":"10.1158\/1078-0432.CCR-11-1203","article-title":"A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma","volume":"17","author":"Eigentler","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0275","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/bjc.2011.183","article-title":"A randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma","volume":"105","author":"O'Day","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0280","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0285","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/cncr.23987","article-title":"Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A","volume":"115","author":"Perez","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0290","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/CMR.0b013e3283390365","article-title":"A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma","volume":"20","author":"Vihinen","year":"2010","journal-title":"Melanoma Res"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0295","doi-asserted-by":"crossref","first-page":"5862","DOI":"10.1158\/1078-0432.CCR-10-2363","article-title":"Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors","volume":"16","author":"Del Vecchio","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0300","doi-asserted-by":"crossref","first-page":"476s","DOI":"10.1200\/jco.2009.27.15_suppl.9061","article-title":"Nab-paclitaxel and bevacizumab as first-line therapy in patients with unresectable stage III and IV melanoma","volume":"27","author":"Boasberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0305","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1200\/JCO.2007.15.7636","article-title":"Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma","volume":"27","author":"Hauschild","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0310","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1038\/sj.onc.1206454","article-title":"Apoptosis and melanoma chemoresistance","volume":"22","author":"Soengas","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0315","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1200\/JCO.2006.06.0483","article-title":"Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group","volume":"24","author":"Bedikian","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0320","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.ejca.2009.04.016","article-title":"LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)","volume":"45","author":"Agarwala","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0325","doi-asserted-by":"crossref","first-page":"7277","DOI":"10.1158\/1078-0432.CCR-09-1245","article-title":"ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors","volume":"15","author":"Palma","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0330","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/jid.2008.379","article-title":"Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide","volume":"129","author":"Sinnberg","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0335","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1038\/sj.jid.5700872","article-title":"Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice","volume":"127","author":"Thallinger","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0340","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1158\/0008-5472.CAN-08-3767","article-title":"Active Notch1 confers a transformed phenotype to primary human melanocytes","volume":"69","author":"Pinnix","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0345","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.4161\/cbt.8.21.9921","article-title":"Emerging role of Notch signaling in epidermal differentiation and skin cancer","volume":"8","author":"Panelos","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0350","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.cellsig.2011.03.002","article-title":"Hedgehog signaling in skin cancers","volume":"23","author":"Li","year":"2011","journal-title":"Cell Signal"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0355","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.canlet.2011.06.008","article-title":"Overexpression of Notch ligand Dll1 in B16 melanoma cells leads to reduced tumor growth due to attenuated vascularization","volume":"309","author":"Zhang","year":"2011","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0360","doi-asserted-by":"crossref","first-page":"e25264","DOI":"10.1371\/journal.pone.0025264","article-title":"The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma","volume":"6","author":"Huynh","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0365","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1158\/0008-5472.CAN-08-2088","article-title":"gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity","volume":"69","author":"Meng","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0370","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/CMR.0b013e32830e3936","article-title":"Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group","volume":"18","author":"Eigentler","year":"2008","journal-title":"Melanoma Res"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0375","first-page":"170","article-title":"Adjuvant chemotherapy as a component of complex treatment for skin melanoma","volume":"54","author":"Kudriavtsev","year":"2008","journal-title":"Vopr Onkologii"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0380","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00000637-199201000-00016","article-title":"Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study","volume":"28","author":"Saba","year":"1992","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0385","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1200\/JCO.2005.04.5344","article-title":"Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma","volume":"24","author":"Lewis","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0390","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/00008390-199812000-00010","article-title":"Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases","volume":"8","author":"Buzaid","year":"1998","journal-title":"Melanoma Res"},{"key":"10.1016\/j.clindermatol.2012.08.016_bb0395","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/annonc\/mdp593","article-title":"Phase II trial of neoadjuvant temozolomide in resectable melanoma patients","volume":"21","author":"Shah","year":"2010","journal-title":"Ann Oncol"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X12001861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X12001861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T04:08:43Z","timestamp":1715227723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X12001861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0738081X12001861"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2012.08.016","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}